Open AccessS143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON‐RESPONSE IN PATIENTS TREATED WITH FIXED‐DURATION VENETOCLAX‐OBINUTUZUMAB
Author(s) -
AlSawaf O.,
Jin H. Y.,
Zhang C.,
Choi Y.,
Balasubramanian S.,
Robrecht S.,
Kotak A.,
Chang N.,
Fink A.M.,
Tausch E.,
Schneider C.,
Ritgen M.,
Kreuzer K.A.,
Chyla B.,
Paulson J.,
Eichhorst B.,
Stilgenbauer S.,
Jiang Y.,
Hallek M.,
Fischer K.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843464.25165.55
Subject(s) - venetoclax , oncology , minimal residual disease , medicine , ighv@ , population , transcriptome , biology , gene , leukemia , gene expression , genetics , chronic lymphocytic leukemia , environmental health